PYXS
Pyxis Oncology Inc

2,465
Mkt Cap
$214.58M
Volume
0.00
52W High
$5.39
52W Low
$0.8332
PE Ratio
-2.18
PYXS Fundamentals
50D MA
$2.26
Beta
1.24
Avg. Volume
863,475.62
EPS (Annual)
-$1.32
P/B
2.45
Rev/Employee
$366,954.54
Loading...
Loading...
News
all
press releases
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
Zacks·10d ago
News Placeholder
More News
News Placeholder
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know
Pyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·11d ago
News Placeholder
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Zacks·11d ago
News Placeholder
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks·1mo ago
News Placeholder
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Zacks·2mo ago
News Placeholder
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. Latest Ratings for PYXS...
Benzinga·1y ago
News Placeholder
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc...
PR Newswire·1y ago
News Placeholder
Pyxis Oncology, Inc. Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology, Inc. (NASDAQ: PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago...
Benzinga·1y ago
News Placeholder
Pyxis Oncology (NASDAQ:PYXS) vs. NewAmsterdam Pharma (NASDAQ:NAMS) Financial Survey
Pyxis Oncology (NASDAQ:PYXS - Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the...
Ticker Report·2y ago
News Placeholder
Pyxis Oncology (PYXS, $4.81) Aroon Indicator entered a Downtrend on April 01, 2024.
For the last three days, A.I.dvisor has detected that PYXS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·2y ago

Latest PYXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.